Sign in Subscribe
COVID-19 vaccines

Troubled Vaccine Manufacturer Emergent BioSolutions Praises Itself with CEO's 51 Percent Compensation Boost

Strategic Insights

— 2 min read

Christopher Rowland, an executive at Emergent BioSolutions, the troubled manufacturer at the heart of Johnson & Johnson's coronavirus vaccine production problems, received a 51 percent increase in total compensation in 2020, to $5.6 million, according to a public filing. The company's annual proxy disclosure said CEO Robert Kramer received $893,000 in salary, a $1.2 million bonus, $2.1 million in stock awards, and $1.4 million in stock options. The company cited its response to the pandemic, including the expansion of its contract manufacturing business and a successful bond offering, as factors in Kramer's bonus.

Key Takeaways:

  • CEO Robert Kramer's total compensation increased by 51 percent in 2020 to $5.6 million, with a salary of $893,000, a $1.2 million bonus, $2.1 million in stock awards, and $1.4 million in stock options.
  • Emergent's 2020 financial success was fueled by a burst of federal spending to fight the coronavirus pandemic, including a $628 million federal contract to upgrade and reserve capacity.
  • Manufacturing problems at Emergent, including contamination of Johnson & Johnson's raw vaccine substance, prompted the federal government to remove all production of AstraZeneca's product from the plant and forced Johnson & Johnson to take direct control of manufacturing.
  • Government officials had documented warning signs at Emergent, including concerns about employee training, record-keeping, and testing procedures, and a federal official warned in June 2020 that Emergent would need to be closely monitored.
  • Emergent received another $23 million from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to purchase more vaccine manufacturing equipment.

Statistics:

  • Total compensation for CEO Robert Kramer rose to $5.6 million in 2020, a 51 percent increase.
  • Emergent's revenue increased by 41 percent in 2020.
  • Emergent received $628 million in a federal contract to upgrade and reserve capacity in 2020.
  • Johnson & Johnson's raw vaccine substance was contaminated, representing up to 15 million doses.
  • The federal government removed all production of AstraZeneca's product from Emergent's plant.
  • Johnson & Johnson took direct control of manufacturing of its vaccine at Emergent's plant.
  • Government officials had documented warning signs at Emergent in April 2020, including concerns about employee training and testing procedures.
  • A federal official warned in June 2020 that Emergent would need to be closely monitored.

Sources:

  • Public filing by Emergent BioSolutions.
  • The Washington Post.
  • The New York Times.
  • Annual proxy disclosure by Emergent BioSolutions.
  • U.S. Biomedical Advanced Research and Development Authority (BARDA).

Read more